U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Febrile Neutropenia, CTCAE

MedGen UID:
1633017
•Concept ID:
C4553819
•
Finding

Definition

A disorder characterized by an ANC <1000/mm3 and a single temperature of >38.3 degrees C (101 degrees F) or a sustained temperature of >=38 degrees C (100.4 degrees F) for more than one hour [from NCI]

Professional guidelines

PubMed

Use and misuse of common terminology criteria for adverse events in cancer clinical trials.
Zhang S, Liang F, Tannock I
BMC Cancer 2016 Jul 4;16:392. doi: 10.1186/s12885-016-2408-9. PMID: 27377548Free PMC Article
Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events.
Zhong X, Lim EA, Hershman DL, Moinpour CM, Unger J, Lee SM
J Oncol Pract 2016 Mar;12(3):e270-80, 245-6. Epub 2016 Feb 23 doi: 10.1200/JOP.2015.006106. PMID: 26907453Free PMC Article

Recent clinical studies

Etiology

Prophylaxis of chemotherapy-induced neutropenia with lipegfilgrastim in patients with lung cancer: final results from the non-interventional study NADIR.
Geßner C, Fietz T, Losem C, Lück A, Schulz H, Niemeier B, Groschek M, Eschenburg H, Weide R, Kretzschmar A, Frost N, Hipp J, Harde J, Matillon CD, Grebhardt S, Potthoff K
Curr Med Res Opin 2022 Dec;38(12):2191-2199. Epub 2022 Sep 1 doi: 10.1080/03007995.2022.2113693. PMID: 36047998
Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil.
Ohkura Y, Ueno M, Udagawa H
World J Surg Oncol 2019 Jul 17;17(1):125. doi: 10.1186/s12957-019-1665-x. PMID: 31315622Free PMC Article
Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR.
Fietz T, Lück A, Schulz H, Harde J, Losem C, Grebhardt S, Wolff T, Potthoff K, Müller U, Zaiss M, Kurbacher CM
Curr Med Res Opin 2019 Jul;35(7):1127-1138. Epub 2019 Jan 21 doi: 10.1080/03007995.2018.1560200. PMID: 30557099
Incidence and risk factors of bacterial and fungal infection during induction chemotherapy for high-risk neuroblastoma.
Whittle SB, Williamson KC, Russell HV
Pediatr Hematol Oncol 2017 Aug;34(5):331-342. Epub 2017 Dec 4 doi: 10.1080/08880018.2017.1396386. PMID: 29200325Free PMC Article
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS
Lancet Oncol 2017 Jun;18(6):779-791. Epub 2017 Apr 21 doi: 10.1016/S1470-2045(17)30279-6. PMID: 28438473Free PMC Article

Diagnosis

Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer.
Yanagisawa T, Kimura T, Hata K, Narita S, Hatakeyama S, Enei Y, Atsuta M, Mori K, Obayashi K, Yoshihara K, Kondo Y, Oguchi T, Sadakane I, Habuchi T, Ohyama C, Shariat SF, Egawa S
Prostate 2022 Oct;82(14):1322-1330. Epub 2022 Jun 29 doi: 10.1002/pros.24406. PMID: 35767376
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.
Petrylak DP, Vogelzang NJ, Chatta K, Fleming MT, Smith DC, Appleman LJ, Hussain A, Modiano M, Singh P, Tagawa ST, Gore I, McClay EF, Mega AE, Sartor AO, Somer B, Wadlow R, Shore ND, Olson WC, Stambler N, DiPippo VA, Israel RJ
Prostate 2020 Jan;80(1):99-108. Epub 2019 Nov 19 doi: 10.1002/pros.23922. PMID: 31742767
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS
Lancet Oncol 2017 Jun;18(6):779-791. Epub 2017 Apr 21 doi: 10.1016/S1470-2045(17)30279-6. PMID: 28438473Free PMC Article
Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.
Vulsteke C, Pfeil AM, Maggen C, Schwenkglenks M, Pettengell R, Szucs TD, Lambrechts D, Dieudonné AS, Hatse S, Neven P, Paridaens R, Wildiers H
Breast Cancer Res Treat 2015 Jul;152(1):67-76. Epub 2015 May 28 doi: 10.1007/s10549-015-3437-9. PMID: 26017071
Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study.
Takekuma M, Hirashima Y, Ito K, Tsubamoto H, Tabata T, Arakawa A, Itani Y, Furukawa N, Murakoshi H, Takeuchi S
Gynecol Oncol 2012 Sep;126(3):341-5. Epub 2012 May 15 doi: 10.1016/j.ygyno.2012.05.010. PMID: 22609108

Therapy

PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.
Petrylak DP, Vogelzang NJ, Chatta K, Fleming MT, Smith DC, Appleman LJ, Hussain A, Modiano M, Singh P, Tagawa ST, Gore I, McClay EF, Mega AE, Sartor AO, Somer B, Wadlow R, Shore ND, Olson WC, Stambler N, DiPippo VA, Israel RJ
Prostate 2020 Jan;80(1):99-108. Epub 2019 Nov 19 doi: 10.1002/pros.23922. PMID: 31742767
Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil.
Ohkura Y, Ueno M, Udagawa H
World J Surg Oncol 2019 Jul 17;17(1):125. doi: 10.1186/s12957-019-1665-x. PMID: 31315622Free PMC Article
Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR.
Fietz T, Lück A, Schulz H, Harde J, Losem C, Grebhardt S, Wolff T, Potthoff K, Müller U, Zaiss M, Kurbacher CM
Curr Med Res Opin 2019 Jul;35(7):1127-1138. Epub 2019 Jan 21 doi: 10.1080/03007995.2018.1560200. PMID: 30557099
Incidence and risk factors of bacterial and fungal infection during induction chemotherapy for high-risk neuroblastoma.
Whittle SB, Williamson KC, Russell HV
Pediatr Hematol Oncol 2017 Aug;34(5):331-342. Epub 2017 Dec 4 doi: 10.1080/08880018.2017.1396386. PMID: 29200325Free PMC Article
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS
Lancet Oncol 2017 Jun;18(6):779-791. Epub 2017 Apr 21 doi: 10.1016/S1470-2045(17)30279-6. PMID: 28438473Free PMC Article

Prognosis

PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.
Petrylak DP, Vogelzang NJ, Chatta K, Fleming MT, Smith DC, Appleman LJ, Hussain A, Modiano M, Singh P, Tagawa ST, Gore I, McClay EF, Mega AE, Sartor AO, Somer B, Wadlow R, Shore ND, Olson WC, Stambler N, DiPippo VA, Israel RJ
Prostate 2020 Jan;80(1):99-108. Epub 2019 Nov 19 doi: 10.1002/pros.23922. PMID: 31742767
Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil.
Ohkura Y, Ueno M, Udagawa H
World J Surg Oncol 2019 Jul 17;17(1):125. doi: 10.1186/s12957-019-1665-x. PMID: 31315622Free PMC Article
Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR.
Fietz T, Lück A, Schulz H, Harde J, Losem C, Grebhardt S, Wolff T, Potthoff K, Müller U, Zaiss M, Kurbacher CM
Curr Med Res Opin 2019 Jul;35(7):1127-1138. Epub 2019 Jan 21 doi: 10.1080/03007995.2018.1560200. PMID: 30557099
Incidence and risk factors of bacterial and fungal infection during induction chemotherapy for high-risk neuroblastoma.
Whittle SB, Williamson KC, Russell HV
Pediatr Hematol Oncol 2017 Aug;34(5):331-342. Epub 2017 Dec 4 doi: 10.1080/08880018.2017.1396386. PMID: 29200325Free PMC Article
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS
Lancet Oncol 2017 Jun;18(6):779-791. Epub 2017 Apr 21 doi: 10.1016/S1470-2045(17)30279-6. PMID: 28438473Free PMC Article

Clinical prediction guides

Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study.
Suzuki K, Matsubara N, Kazama H, Seto T, Tsukube S, Matsuyama H
Jpn J Clin Oncol 2019 Dec 27;49(12):1157-1163. doi: 10.1093/jjco/hyz108. PMID: 31361807Free PMC Article
Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil.
Ohkura Y, Ueno M, Udagawa H
World J Surg Oncol 2019 Jul 17;17(1):125. doi: 10.1186/s12957-019-1665-x. PMID: 31315622Free PMC Article
Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.
Vulsteke C, Pfeil AM, Maggen C, Schwenkglenks M, Pettengell R, Szucs TD, Lambrechts D, Dieudonné AS, Hatse S, Neven P, Paridaens R, Wildiers H
Breast Cancer Res Treat 2015 Jul;152(1):67-76. Epub 2015 May 28 doi: 10.1007/s10549-015-3437-9. PMID: 26017071
A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors.
Wakui H, Yamamoto N, Kitazono S, Mizugaki H, Nakamichi S, Fujiwara Y, Nokihara H, Yamada Y, Suzuki K, Kanda H, Akinaga S, Tamura T
Cancer Chemother Pharmacol 2014 Jul;74(1):15-23. Epub 2014 Apr 22 doi: 10.1007/s00280-014-2467-z. PMID: 24752449
A phase II study of weekly docetaxel-cisplatin as first-line treatment for advanced non-small cell lung cancer.
Binder D, Hackenthal M, Graseck L, Schweisfurth H, Schäper C, Krüll M, Temmesfeld-Wollbrück B, Suttorp N, Beinert T, Hellriegel KP
J Thorac Oncol 2009 Sep;4(9):1144-7. doi: 10.1097/JTO.0b013e3181b0f0de. PMID: 19609222

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...